Press Releases - 2020-04-22

Date	Title	Company
22-Apr-2020	Coronavirus (COVID-19) Update: Daily Roundup	U.S. Food and Drug Administration
22-Apr-2020	Alkermes to Host Conference Call to Discuss First Quarter 2020 Financial Results	Alkermes plc
22-Apr-2020	OncoQuest Announces Signing of a Definitive Agreement to Sell Drug Portfolio to Dual Industrial for U.S. $300 Million and Commitment to Fund the Oregovomab Phase 3 Clinical Trial in Frontline Ovarian Cancer	OncoQuest Inc.
22-Apr-2020	FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments	U.S. Food and Drug Administration
22-Apr-2020	Campaigning begins to provide at-risk groups in the UK with the vitamin D they need during COVID-19 self-isolation	Thornton & Ross
22-Apr-2020	Campaigning begins to provide at-risk groups in the UK with the vitamin D they need during COVID-19 self-isolation	Thornton & Ross
22-Apr-2020	Campaigning begins to provide at-risk groups in the UK with the vitamin D they need during COVID-19 self-isolation	Thornton & Ross
22-Apr-2020	Campaigning begins to provide at-risk groups in the UK with the vitamin D they need during COVID-19 self-isolation	Thornton & Ross
22-Apr-2020	Campaigning begins to provide at-risk groups in the UK with the vitamin D they need during COVID-19 self-isolation	Thornton & Ross
22-Apr-2020	COVID-19 – Intergrated Vaccination and Immunodiagnostic Platform	Viravaxx AG
22-Apr-2020	Clinical trials company recognised with royal business award	Innovative Trials
22-Apr-2020	Panthera is open for clinical trials in Manchester	Panthera Biopartners
22-Apr-2020	Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)	Novartis
22-Apr-2020	XenoGesis wins prestigious Queen’s Award for Enterprise in recognition of export growth	XenoGesis
22-Apr-2020	Ricardo helps Isansys scale up production of its life-saving innovation in healthcare	Ricardo
22-Apr-2020	VFMCRP and Cara Therapeutics announce positive results from global KALM-2 pivotal phase-III trial of KORSUVA™ injection in haemodialysis patients with Pruritus	Cara Therapeutics
22-Apr-2020	ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer	ERYTECH Pharma
22-Apr-2020	Futura files for Further Pre-Submission meeting with the FDA following receipt of its Phase 3 clinical study report	Futura Medical plc
22-Apr-2020	FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer	FoRx Therapeutics
22-Apr-2020	NICE approves oral drug VITRAKVI®▼(larotrectinib), the first histology-independent treatment to be made available in England, for children and adults with TRK fusion driven cancer	Larotrectinib